Document Detail


Inactivation of xanthine oxidoreductase is associated with increased joint swelling and nitrotyrosine formation in acute antigen-induced arthritis.
MedLine Citation:
PMID:  15971422     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Arthritis is associated with increased articular formation of nitrotyrosine, which may contribute to injury. Nitrotyrosine is formed by nitration of tyrosine by reactive nitrogen species such as peroxynitrite, the formation of which may be enhanced by xanthine oxidoreductase (XOR), since it can generate nitric oxide from nitrite/nitrate, and superoxide during xanthine metabolism. We hypothesized that inactivation of XOR would protect against antigen-induced arthritis (AIA) and decrease nitrotyrosine formation. METHODS: AIA was induced with methylated bovine serum albumin (mBSA) in three groups of Wistar rats: animals fed on (1) tungsten-enriched chow (0.7 g/kg) (TG), which inactivates XOR, (2) standard chow (SG), and (3) rats treated with allopurinol (50 mg/kg/day; p.o.) (AG). Nitrotyrosine in patella-synovium was quantified by mass spectrometry three weeks after intra-articular (i.a.) antigen injection. RESULTS: Treatment with tungsten, but not allopurinol, suppressed plasma and articular XOR activity at < or = 0.9% of normal levels. XOR inactivation was associated with increased knee swelling 24-48 hrs post i.a. mBSA, compared with controls (mean increase +/- SEM of knee diameter from baseline of 3.3 +/- 0.5, 2.0 +/- 0.3 and 1.9 +/- 0.2 mm in TG, SG and AG (n = 14 each group), respectively; p < 0.05, TG vs SG, ANOVA). Mean ratio of articular nitrotyrosine-tyrosine (+/- SEM) was increased in the XOR-inactivated group, compared with controls: 12.3 +/- 0.7, 9.6 +/- 0.8 and 10.4 +/- 0.5 pg/microg in TG, SG and AG, respectively; p < 0.05, TG vs SG. CONCLUSION: Contrary to expectation, XOR inactivation was associated with increased joint swelling and articular tyrosine nitration in acute AIA, suggesting a novel, protective role for XOR in inflammatory arthritis.
Authors:
R Klocke; A R Mani; K P Moore; D R Blake; P I Mapp
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  23     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2005 May-Jun
Date Detail:
Created Date:  2005-06-23     Completed Date:  2005-08-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  345-50     Citation Subset:  IM    
Affiliation:
Department of Pharmacy & Pharmacology/Schoolfor Health, University of Bath, UK. Rainer.Klocke@dgoh.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allopurinol / therapeutic use
Animals
Arthritis, Experimental / drug therapy,  enzymology*,  pathology
Cattle
Enzyme Inhibitors / therapeutic use
Joints / enzymology*,  pathology
Male
Rats
Rats, Wistar
Serum Albumin, Bovine / administration & dosage
Stifle / drug effects,  pathology,  radiography
Synovial Membrane / drug effects,  enzymology,  pathology
Tungsten / therapeutic use
Tyrosine / analogs & derivatives*,  metabolism*
Xanthine Dehydrogenase / antagonists & inhibitors*,  metabolism
Grant Support
ID/Acronym/Agency:
//Wellcome Trust
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Serum Albumin, Bovine; 315-30-0/Allopurinol; 3604-79-3/3-nitrotyrosine; 55520-40-6/Tyrosine; 7440-33-7/Tungsten; EC 1.17.1.4/Xanthine Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lack of association between TNF-308 polymorphism and the clinical and immunological characteristics ...
Next Document:  Influence of clinical and immunological parameters on the health-related quality of life of patients...